chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Hospitalized (9.16.21);  COVID-19 positive (9.16.21);  Fully Vaccinated  HISTORY OF PRESENT ILLNESS: Pt is a 81 y.o. female who presents today with aspiration event and COVID-19 pneumonia.  Patient has a history of HTN, hypothyroidism, chronic pain requiring dilaudid, gabapentin, valium, and insomnia on Ambien. She lives at home with her husband.  She was eating a bagel this morning, started gagging, coughing, and having difficulty breathing. EMS was called, and upon arrival she had saturations in the 70s, improved to 80% on a non rebreather. Arrived in the ER, was given fluid bolus. Food was removed from the posterior pharynx. She was intubated for hypoxemia and altered mental status.  COVID-19 PCR was positive on routine work up, she did have bilateral infiltrates on CXR. WBC 12, lactate 2.2, BNP 600, Cr of 1.27, GFR on 40 (unclear baseline), and negative CT head. Unasyn and vancomycin were given in the ER. They also gave narcan but no significant improvement. Upon arrival to the medical ICU, patient was awake, but not following commands on propofol drip. She required minimal ventilator support, 5/5, fio2 of 35%. Hypertensive and otherwise hemodynamically stable and afebrile.  Pneumonia due to COVID-19 virus.  ASSESSMENT / PLAN: 81 year old female with history of HTN, hypothyroidism, chronic pain on opioids and benzodiazepines, insomnia on Ambien, presents with acute hypoxemic respiratory failure in the setting of aspiration event, and bilateral pulmonary infiltrates and tested positive COVID-19. She was intubated 9/16/21 for hypoxemia and altered mentation Assessment & Plan Unclear when patient developed symptoms.  Incidentally tested positive 9/16/21. Has bilateral pulmonary infiltrates on CXR.  Start Remdesivir (FD 9/16/21) Start Decadron 6 mg daily (FD 9/16/21)  Note from 9.23.21:  Acute hypoxic respiratory failure-Felt secondary to COVID infection as well as aspiration pneumonia COVID 19 infection COVID test was positive 9/16 and symptom onset was also 9/16 Patient was intubated from 09/16 to 9/17 Was previously on 4 L of oxygen, weaned down to 2 L and then was off during the daytime yesterday.  She had required oxygen overnight and also requiring 2 L of oxygen this morning Will consult pulmonary rehab to evaluate for home oxygen Completed remdesivir Continues on Decadron Continue incentive spirometry  CT angiogram thorax  did not reveal any evidence of pulmonary embolus but showed severe pulmonary emphysema/large hiatal hernia and mild cardiomegaly as well as hazy ground-glass opacity in the posterior right lung
Immediately after vaccine administration pt. became pale, had vasovagal syncope, did not hurt head. Pt lost bladder control. Pt revived within 15 seconds later. Mom notified.
Client received TWINRIX at health department on 9-19-2011 approximately at 4:30pm. At approx. 3am on 9-20, she woke up feeling hot and having chills. She had itching on her head, armpits, lips, labia and could feel "blotchy hives" on her back. She did not have any tightness of the throat at that time. She took BENADRYL at that time and again at 11-11:30am on Tuesday. She felt ok all day Wednesday and then woke up at 3am on Thursday feeling hot and sweating. She had swelling of her lips with tingling and numbness. She took a BENADRYL at that time. Patient called me late morning and I returned her call about 1:30pm. She asked me if she could take anything else to help with the reaction. I told her to take either generic CLARITIN or ZYRTEC. She thought she had some at home so took a ZYRTEC at approximately 1:30-2:00 pm. She also reported that her throat felt tight with that lasting until about mid afternoon. I called patient about 7pm and asked how she was doing and she told me that she had taken a ZYRTEC and that all of her swelling was gone along with the itching. She said she was "up and going and does not feel bad at all". She also reported that her swelling had completely resolved.
Itching at the injection site; Redness at injection site; Rashy at injection site; Rash all over the body; headache; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (Itching at the injection site), VACCINATION SITE ERYTHEMA (Redness at injection site), VACCINATION SITE RASH (Rashy at injection site), RASH (Rash all over the body) and HEADACHE (headache) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination.     The patient's past medical history included Heart disorder and Allergy.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Feb-2021, the patient experienced VACCINATION SITE PRURITUS (Itching at the injection site), VACCINATION SITE ERYTHEMA (Redness at injection site), VACCINATION SITE RASH (Rashy at injection site), RASH (Rash all over the body) and HEADACHE (headache). On 20-Feb-2021, HEADACHE (headache) had resolved. At the time of the report, VACCINATION SITE PRURITUS (Itching at the injection site), VACCINATION SITE ERYTHEMA (Redness at injection site), VACCINATION SITE RASH (Rashy at injection site) and RASH (Rash all over the body) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment and concomitant medications were not provided by reporter.   Reporter did not allow further contact
unable to lift her arm/patient's difficulty in lifting lasted 3 days; red stripe that appeared 5 inches below and 5 inches above injection site; injection site was hot, swollen, there was pain; injection site was hot, swollen, there was pain; injection site was hot, swollen, there was pain; This spontaneous report was received from an office manager referring to a 38-year-old adult female patient. The patient's concurrent condition included rheumatoid arthritis and immunodeficiency. The patient's medical history and drug allergies were not reported. The patient's concomitant therapy included methotrexate. On 12-SEP-2019, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) via intramuscular route for immunodeficiency (lot/batch number and expiry date were reported as S009945 and 10-AUG-2020 respectively) (strength and dose were not reported). On 13-SEP-2019, the patient had complaints of being unable to lift her arm (arm where dose was administered) which lasted for 3 days as her range of motion was limited with swelling (movement disorder), there was a red stripe that appeared 5 inches below and 5 inches above injection site (injection site erythema), injection site was hot (injection site warmth), swollen (injection site swelling) and there was pain to touch (injection site pain). The patient was treated for the events with Benadryl, compresses and ibuprofen and sought medical attention. There was no overdose and product quality complaint reported. The adverse event was not cancer and the patient did not die. The outcome of the events were reported as recovering. The causality of the events with respect to pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) was not reported.
Pt. felt nauseated and faint 5 minutes after the immunizations were given. Her color was pale and her skin diaphoretic. Her VS remained stable at BP 100/70, P 82 R 16. She remained arousable, followed commands and had no seizure activity. She laid on the sofa in Kids Health Connection for one hour and 20 minutes. She slept lightly but was arousable. She drank water without difficulty, ate lunch in the Health Center and then returned to class. She was checked on 5/26/2011 and had no further problems. A phone call to her mother confirmed that she is fine, other than a sore arm from her TDAP.
Adverse immune system response.  Redness and swelling under arms for more than a month and has not ceased
Dizziness Tired Muscle & joint pain swelling of lymph nodes terrible headache chills fever nausea
1 vial was thawed out 9Oct2021 and then was punctured and put back in freezer; patient receiving expired vaccine/Dose administered after 30-day Use By Date or after manufacturer date of expiry; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (patient receiving expired vaccine/Dose administered after 30-day Use By Date or after manufacturer date of expiry) and WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (1 vial was thawed out 9Oct2021 and then was punctured and put back in freezer) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 027B21A and 027B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 09-Oct-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Nov-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (patient receiving expired vaccine/Dose administered after 30-day Use By Date or after manufacturer date of expiry). On an unknown date, the patient experienced WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (1 vial was thawed out 9Oct2021 and then was punctured and put back in freezer). On 04-Nov-2021, EXPIRED PRODUCT ADMINISTERED (patient receiving expired vaccine/Dose administered after 30-day Use By Date or after manufacturer date of expiry) had resolved. At the time of the report, WRONG TECHNIQUE IN PRODUCT USAGE PROCESS (1 vial was thawed out 9Oct2021 and then was punctured and put back in freezer) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   2 patients were administered a first dose on 9Oct2021. 1 patient given 2nd dose 4Nov2021. Concomitant medications was not reported. Treatment medications was not reported. This case concerns a patient of unknown age and gender with no relevant medical history, who experienced the event of expired product administered. The event expired product administered occurred right after the unknown dose number of mRNA-1273 vaccine administration. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.   Most recent FOLLOW-UP information incorporated above includes: On 10-Nov-2021: follow up 10-nov-21 contain no new information On 15-Nov-2021: Follow up received included,reporter information ,suspect drug and event  information was updated.; Sender's Comments: This case concerns a patient of unknown age and gender with no relevant medical history, who experienced the event of expired product administered. The event expired product administered occurred right after the unknown dose number of mRNA-1273 vaccine administration. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.
Pt reported numbness in hands and feet as well as severe fatigue where she could barely get out of bed accompanied with nausea and a fever.
Administered at 10:43a, woke following morning with swollen site of injection. Came into pharmacy at 12:16p on 9/25/22 to show us. It was warm to touch, slight redness and swollen. About the size of a softball. No other symptoms, was not bothering her, just felt swollen and sore. Suggested 600mg IBU and 25mg benadryl or topical.
Patient was 17 years old at time of vaccination. This vaccine is indicated for 18 years and older. Patient was attempted to be contacted 2 times before leaving a voicemail to return call. No returned call.
After my vaccine, on 03-10-2021 at 1:00am, I experienced intense headaches and muscle body aches. I called my PCP due to my symptoms and loss of taste and smell.  As of today, I am concerned since I have not regained my loss of taste and smell.
PATIENT STATES THAT HE BECAME VERY TIRED AND LIGHTHEADED FOLLOWING VACCINATION.  HE STATES HE WOKE UP IN THE MIDDLE OF THE NIGHT AT SOME POINT, BECAME LIGHTHEADED AND LOST CONSCIOUSNESS/PASSED OUT AND SUFFERED A FALL AS A RESULT OF THIS.
The patient developed a rash from her shoulder on up, following vaccination on 12/18/00. The patient saw her PCP 12/19/00, she was treated with Benadryl.  The rash increased to the trunk area through out the day, no trouble breathing, no hospitalization.
My eyes began watering and began to burn. This lasted 5 minutes. It has happened two more times since I got the vaccine.
Patient described getting a case of shingles on the left side of her body from her neck down to her buttocks.
Inappropriate schedule of vaccine administered; No additional AE; This spontaneous report was received from a nurse refers to a 4-year-old female patient. No information on patient's medical history, current conditions and concomitant medications was provided.      On 21-FEB-2019, the patient was vaccinated with first dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) for prophylaxis (exact dose, route of administration, lot number and expiration date were not provided). On 16-MAY-2019, the patient was vaccinated with second dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) for prophylaxis (exact dose, route of administration, lot number and expiration date were not provided) (inappropriate schedule of product administration and no adverse event).; Sender's Comments:  US-009507513-2307USA009252: US-009507513-2307USA011295:
Patient with onset of dizzy spells, headaches, body pain post vaccine, worsened after 2nd. Diagnosed with POTS Saw PEDI Neuro
2 large wheals on both upper arms in deltoid areas of both right and left arms- Approx. 10:30AM. At 5:30 PM developed large wheal right cheek, both thighs. Extremely itchy-treated with Benadryl and ice. Following day 4/13/04 Rash subsided, skin however still itchy. By 4/14/02 no more symptoms
Pt recvd 3 doses of Engerix-B, 3rd dose given 12OCT90 & it was determined that pt had a negative Hep B titer; 4th dose of Engerix-B given 1FEB91 & subsequent Hep-B titer was also negative; 5th dose may be needed;
diffuse macular erythematous rash chest, abdominal, back, extending to groin area, no injection site erythema on the RUE. patient received injection approx 12:27pm on 10/19/22 reported having rash approx 10/20/22 22:00pm, was given 50mg po x1 benedryl  - seen again on 10/21 as rash has not resolved and is as stated above, now given 50mg po x1 dose now prednisone at 13:30 and RX for 50mg po x 6 days starting 10/22/22. will continue to follow.
For the next month, he experienced severe headaches worse than a migraine, overall body ache, and pain, abdominal pain, severe exhaustion unable to get up and walk due to fatigue. He had 3 doctor visits prior to having a stroke about 1 month after the vaccine. He was taken to the ER, and put on life support for 4 days. When life-support was stopped, he died.
Loosing hair was coming out everytime i combed it/Hair is so thin now; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 67 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 29Dec2021 (Batch/Lot number: unknown) at the age of 67 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Known allergies: Yes" (unspecified if ongoing), notes: Known allergies: Yes. The patient took concomitant medications. Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: ew0182, Location of injection: Arm Right), administration date: 11Jun2021, when the patient was 66 years old, for COVID-19 Immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: ew0173, Location of injection: Arm Left), administration date: 21May2021, when the patient was 66 years old, for COVID-19 Immunization.  The following information was reported: ALOPECIA (non-serious) with onset 31Dec2021, outcome "recovered with sequelae", described as "Loosing hair was coming out everytime i combed it/Hair is so thin now". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of alopecia.  Additional information: The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received other medications within 2 weeks of vaccination. Within a day or 2 patient started loosing hair, which was coming out everytime she combed it. This lasted for about 5 weeks. Patient hair was so thin now, told cardiologist and sent her for thyroid test, which came back good. Prior to vaccination, the patient not diagnosed with COVID-19. Since the vaccination, the patient been tested for COVID-19. Other medical history: Yes.  The lot number for bnt162b2 was not provided and will be requested during follow up.
Initially felt unusually tired and achy.  Went to bed early, then felt abnormally cold (wrapped myself in blankets).  Fever (too weak to get thermometer to see how high fever was).  Started shivering.  Headache.  Significant weakness and dizziness.  Frequent urination that night.  Sore arm (site of vaccination).  By morning (7:30 a.m.) symptoms began to get better.
slight headache; hot to the touch; little tiny bumps on my upper right chest near my armpit; nausea; tender; The injection site was swollen about the size of a baseball; pain in my ankles; The injection site had a red mark; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (hot to the touch), PAPULE (little tiny bumps on my upper right chest near my armpit), NAUSEA (nausea), VACCINATION SITE PAIN (tender) and VACCINATION SITE SWELLING (The injection site was swollen about the size of a baseball) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 21-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Mar-2021, the patient experienced VACCINATION SITE WARMTH (hot to the touch), PAPULE (little tiny bumps on my upper right chest near my armpit), NAUSEA (nausea), VACCINATION SITE PAIN (tender), VACCINATION SITE SWELLING (The injection site was swollen about the size of a baseball), ARTHRALGIA (pain in my ankles) and VACCINATION SITE ERYTHEMA (The injection site had a red mark). On 22-Mar-2021, the patient experienced HEADACHE (slight headache). At the time of the report, VACCINATION SITE WARMTH (hot to the touch), PAPULE (little tiny bumps on my upper right chest near my armpit), NAUSEA (nausea), VACCINATION SITE PAIN (tender), VACCINATION SITE SWELLING (The injection site was swollen about the size of a baseball), ARTHRALGIA (pain in my ankles), VACCINATION SITE ERYTHEMA (The injection site had a red mark) and HEADACHE (slight headache) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported.  No treatment medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 22-Jun-2021: Updated outcome for all events as recovered/resolved.
Hives from shoulder to wrist on (L) arm. Resolved after one dose of BENADRYL.
Admitted with chest pain and lost of taste/smell.  Confirmed COVID (+) after being fully vaccinated for over 1 month.
Patient tested positive for COVID on 1/18/2021.  Her symptoms started 1/17/2021.
A few days after his first covid vaccine, he had sores on his first 3 finger tips that were painful and then peeled. "Blisters" but not fluid filled. No lesions on 4th and 5 th digits or on his toes. No fever. O: peeling of skin at tips of thumb, first two fingers bilaterally, NT. Rest of fingers/toes nml.
Arm itching; Sore arm, tenderness; Arm redness; Arm swelling; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (Arm itching), VACCINATION SITE PAIN (Sore arm, tenderness), VACCINATION SITE ERYTHEMA (Arm redness) and VACCINATION SITE SWELLING (Arm swelling) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039K202A and 032B21A) for COVID-19 vaccination.   The patient's past medical history included Chronic sinusitis in 2000. Concurrent medical conditions included Drug allergy (Astelyn nasal spray). Concomitant products included CALCIUM for Supplementation therapy, AMOXICILLIN SODIUM, CLAVULANATE POTASSIUM (AUGMENTIN [AMOXICILLIN SODIUM;CLAVULANATE POTASSIUM]) for Tooth ache, VITAMIN B NOS (B-COMPLEX [VITAMIN B NOS]), VITAMIN D [VITAMIN D NOS], CURCUMA LONGA (TURMERIC [CURCUMA LONGA]) and UBIDECARENONE (COQ10 [UBIDECARENONE]) for an unknown indication.   On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PRURITUS (Arm itching), VACCINATION SITE PAIN (Sore arm, tenderness), VACCINATION SITE ERYTHEMA (Arm redness) and VACCINATION SITE SWELLING (Arm swelling). The patient was treated with HYDROCORTISONE (HYDROCORTISONE 1% IN ABSORBASE) (topical) for Itch, at a dose of cream. At the time of the report, VACCINATION SITE PRURITUS (Arm itching), VACCINATION SITE PAIN (Sore arm, tenderness), VACCINATION SITE ERYTHEMA (Arm redness) and VACCINATION SITE SWELLING (Arm swelling) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication include MVI   Most recent FOLLOW-UP information incorporated above includes: On 10-Jun-2021: Follow-up received addition of relevant history ,addition of patient demography, addition of concomitant medications, addition of second Moderna dose vaccine; Sender's Comments: Based on the current available information and temporal association between the use of the product and the events, a causal relationship cannot be excluded.
Extreme pain in deltoid area at the site of injection on left arm. Unable to lift arm to shoulder height without extreme pain. Although I have had some relief, I am still not able to exercise or leverage my left arm, 7 months later.
mother consenting to the administration of a Covid vaccine. She indicated on a legal signed form that  had not received a Covid vaccine. Upon entering the vaccine into IRIS, it was discovered that he had already completed the Pfizer series. (Pfizer EW0173 on 05/28/2021 and Pfizer EW0181 on 06/18/2021).  This RN spoke with mother on 08/27 and 08/30. Mother denies side effects and reports that he is feeling fine. Mother reports that she wanted the family "double vaccinated" for upcoming travel. Mother instructed to call SCPH with any adverse effects that occur. Mother verbalized understanding.
Injection site pain, swelling, muscle aches & fatigue, dehydration, hair loss
Information has been received from a physician concerning a 15 year old female patient with a history of obsessive-compulsive disorder and premenstrual tension and no allergies who was vaccinated intramuscularly with three 0.5ml doses of GARDASIL (respective lot#s are 665547/1318Y, 662304/1013Y and 662299/1099Y also reported as "099Y") respectively on 24-NOV-2009, 20-APR-2010 and 09-JUN-2010. Concomitant therapy included LEXAPRO and ZOVIA. On 09-JUN-2010, after receiving the third dose, the patient remained in the office for 20 minutes. When checked she complained of numbness and tingling throughout her body, and it was hard for her to move. She was seen by doctor, observed and rested in the office for 25 minutes and then felt better. She then left the office. At the time of this report, the patient had recovered. Additional information has been requested.
I had congestive in my chest and nose. I had weakness and a fever. I had brain fog in my head. These lasted for about 5 or 6 days. The congestive lasted for about 2 weeks. I went on Dec 22nd for a Covid-19 test, positive result.